RxDoctor Payments Data

David Kaminetzky, MD

Hematology & Oncology · New York, NYNPI 1083702245

Payments from drug & device makers

$420,957in general payments, 2019–2025

Across 17 payments — averaging $24,762 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$364K
  • Karyopharm Therapeutics Inc.$57K

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bristol Myers Squibb12$363,559
Karyopharm Therapeutics Inc.5$57,398

How this compares

$420,957 in reported general payments places this provider in the 80th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$124,838
Medicare patients
538
Services billed
1,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydroxyurea21$154

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →